<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37451321</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0542</ISSN><JournalIssue CitedMedium="Internet"><Volume>261</Volume><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Immunology letters</Title><ISOAbbreviation>Immunol Lett</ISOAbbreviation></Journal><ArticleTitle>Epstein-Barr virus and genetic risk variants as determinants of T-bet<sup>+</sup> B cell-driven autoimmune diseases.</ArticleTitle><Pagination><StartPage>66</StartPage><EndPage>74</EndPage><MedlinePgn>66-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.imlet.2023.07.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-2478(23)00118-9</ELocationID><Abstract><AbstractText>B cells expressing the transcription factor T-bet are found to have a protective role in viral infections, but are also considered major players in the onset of different types of autoimmune diseases. Currently, the exact mechanisms driving such 'atypical' memory B cells to contribute to protective immunity or autoimmunity are unclear. In addition to general autoimmune-related factors including sex and age, the ways T-bet<sup>+</sup> B cells instigate autoimmune diseases may be determined by the close interplay between genetic risk variants and Epstein-Barr virus (EBV). The impact of EBV on T-bet<sup>+</sup> B cells likely relies on the type of risk variants associated with each autoimmune disease, which may affect their differentiation, migratory routes and effector function. In this hypothesis-driven review, we discuss the lines of evidence pointing to such genetic and/or EBV-mediated influence on T-bet<sup>+</sup> B cells in a range of autoimmune diseases, including systemic lupus erythematosus (SLE) and multiple sclerosis (MS). We provide examples of how genetic risk variants can be linked to certain signaling pathways and are differentially affected by EBV to shape T-bet<sup>+</sup> B-cells. Finally, we propose options to improve current treatment of B cell-related autoimmune diseases by more selective targeting of pathways that are critical for pathogenic T-bet<sup>+</sup> B-cell formation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bogers</LastName><ForeName>Laurens</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MS Center ErasMS, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, Rotterdam 3015 CN, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuiper</LastName><ForeName>Kirsten L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>MS Center ErasMS, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, Rotterdam 3015 CN, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smolders</LastName><ForeName>Joost</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MS Center ErasMS, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, Rotterdam 3015 CN, The Netherlands; MS Center ErasMS, Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam 3015 CN, The Netherlands; Netherlands Institute for Neuroscience, Neuroimmunology research group, Amsterdam 1105 BA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rip</LastName><ForeName>Jasper</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MS Center ErasMS, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, Rotterdam 3015 CN, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Luijn</LastName><ForeName>Marvin M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>MS Center ErasMS, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, Rotterdam 3015 CN, The Netherlands. Electronic address: m.vanluijn@erasmusmc.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Immunol Lett</MedlineTA><NlmUniqueID>7910006</NlmUniqueID><ISSNLinking>0165-2478</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune disease</Keyword><Keyword MajorTopicYN="N">B-cell differentiation</Keyword><Keyword MajorTopicYN="N">Epstein&#x2013;Barr virus</Keyword><Keyword MajorTopicYN="N">Genetic susceptibility</Keyword><Keyword MajorTopicYN="N">Pathogenic</Keyword><Keyword MajorTopicYN="N">T-bet(+) B cells</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest M.M.v.L. received research support from EMD Serono, Merck, GSK and Idorsia Pharmaceutical Ltd. J.S. received lecture and/or consultancy fees from Biogen, Merck, Novartis and Sanofi-Genzyme. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>15</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37451321</ArticleId><ArticleId IdType="doi">10.1016/j.imlet.2023.07.006</ArticleId><ArticleId IdType="pii">S0165-2478(23)00118-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>